de la Torre Pola, Meyer Daniel K, Reboli Annette C
Division of Infectious Diseases, Cooper University Hospital, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, NJ, USA.
Future Microbiol. 2008 Dec;3(6):593-601. doi: 10.2217/17460913.3.6.593.
A third echinocandin, anidulafungin, has recently been approved for Candida infections in the non-neutropenic patient. In the EU it is indicated for invasive candidiasis; in 2006 it was approved in the USA for candida esophagitis, candidemia, and two types of invasive infections, peritonitis and intra-abdominal abscesses. It is fungicidal against Candida species and fungistatic against Aspergillus species. In addition to its favorable tolerability in studies to date, it does not need adjustment for renal or hepatic insufficiency and has no known drug interactions. A steady state concentration can be achieved on day 2 following a loading dose of twice the maintenance concentration on day 1, and the drug is administered intravenously once daily. Cross resistance with other classes of antifungals is not a concern as it possesses a unique mechanism of action.
第三种棘白菌素类药物阿尼芬净最近已被批准用于非中性粒细胞减少患者的念珠菌感染。在欧盟，它被用于侵袭性念珠菌病；2006年在美国被批准用于念珠菌食管炎、念珠菌血症以及两种侵袭性感染，即腹膜炎和腹腔内脓肿。它对念珠菌属具有杀菌作用，对曲霉属具有抑菌作用。除了在迄今为止的研究中具有良好的耐受性外，它不需要因肾功能或肝功能不全而调整剂量，并且没有已知的药物相互作用。在第1天给予维持浓度两倍的负荷剂量后，第2天可达到稳态浓度，且该药物每日静脉注射一次。由于其具有独特的作用机制，因此与其他类抗真菌药物不存在交叉耐药问题。
